Perioperative and long-term outcomes after percutaneous thrombectomy of arteriovenous dialysis access grafts.


Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
12 2020
Historique:
received: 28 10 2019
accepted: 09 03 2020
pubmed: 15 4 2020
medline: 16 3 2021
entrez: 15 4 2020
Statut: ppublish

Résumé

Maintenance of functional arteriovenous grafts (AVGs) for dialysis is difficult secondary to low primary patency, need for reinterventions, and limited alternative dialysis access options. We assessed our experience with percutaneous thrombectomy for treatment of occluded AVGs. We performed a retrospective analysis of all percutaneous thrombectomies for AVGs from 2015 to 2017. These were generally performed using mechanical thrombectomy and occasional chemical tissue plasminogen activator thrombolysis, over-the-wire balloon embolectomy for inflow, and adjunctive inflow and outflow interventions as necessary. Perioperative outcomes, long-term patency, reinterventions, and need for new permanent access placement were analyzed. There were 218 percutaneous thrombectomies performed on 86 AVGs in 77 patients. Approximately half (53.2%) of the patients were male and 68.8% were black. Mean age was 61.1 ± 13.0 years. At the time of thrombectomy, 73.8% underwent venous outflow interventions and 4.5% underwent arterial inflow interventions. Within 30 days, 24.8% of declotted grafts underwent repeated percutaneous thrombectomy, 14.3% required tunneled dialysis catheter placement, 4% developed minor access site or graft infections, and one patient underwent surgical arterial thrombectomy for arm ischemia. There were no venous thromboembolic, cardiopulmonary, or cerebrovascular complications or clinically significant pulmonary embolism. At 1 year and 3 years after percutaneous thrombectomy, freedom from repeated thrombosis was 37% and 18%, respectively, and freedom from new dialysis access placement was 66% and 51%, respectively. Overall patient survival was 82% at 3 years. Percutaneous thrombectomy of AVGs is safe and is associated with acceptable patency rates. This minimally invasive method extends AVG use for these high-risk patients with limited dialysis access options.

Identifiants

pubmed: 32289439
pii: S0741-5214(20)30486-9
doi: 10.1016/j.jvs.2020.03.032
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2107-2112

Informations de copyright

Copyright © 2020 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Nkiruka Arinze (N)

Division of Vascular and Endovascular Surgery, Boston University, School of Medicine, Boston Medical Center, Boston, Mass.

Tyler Ryan (T)

Division of Vascular and Endovascular Surgery, Boston University, School of Medicine, Boston Medical Center, Boston, Mass.

Rohit Pillai (R)

Division of Vascular and Endovascular Surgery, Boston University, School of Medicine, Boston Medical Center, Boston, Mass.

Rajendran Vilvendhan (R)

Division of Interventional Radiology, Boston University, School of Medicine, Boston Medical Center, Boston, Mass.

Alik Farber (A)

Division of Vascular and Endovascular Surgery, Boston University, School of Medicine, Boston Medical Center, Boston, Mass.

Douglas W Jones (DW)

Division of Vascular and Endovascular Surgery, Boston University, School of Medicine, Boston Medical Center, Boston, Mass.

Denis Rybin (D)

Department of Biostatistics, Boston University, School of Public Health, Boston, Mass.

Scott R Levin (SR)

Division of Vascular and Endovascular Surgery, Boston University, School of Medicine, Boston Medical Center, Boston, Mass.

Thomas W Cheng (TW)

Division of Vascular and Endovascular Surgery, Boston University, School of Medicine, Boston Medical Center, Boston, Mass.

Jeffrey J Siracuse (JJ)

Division of Vascular and Endovascular Surgery, Boston University, School of Medicine, Boston Medical Center, Boston, Mass. Electronic address: jeffrey.siracuse@bmc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH